-
Uncategorized1 month ago
Summit shares descend as PD-1/VEGF asset misses early survival mark
Summit Therapeutics planned an early interim progression-free survival readout for HARMONi-3 in the hope of enabling earlier regulatory engagement—but the early analysis delivered disappointment for the...
-
Uncategorized1 month ago
FDA clears Pfizer, Arvinas’ novel breast cancer therapy despite mixed data
Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s Faslodex but showed no such significant benefit in the...
-
Uncategorized1 month agoSTAT+: Biotech raises $42 million to run Huntington’s disease trial
Gene therapy startup Latus Bio has raised another $42 million to start its first clinical trials, where it will try to sidestep issues that have set...
-
Uncategorized1 month ago
UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases
The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for...
-
Uncategorized1 month ago
What is your AI drug repurposing strategy missing?
Fragmented data limits even the most advanced oncology AI. Curated knowledge changes that. Read More
-
Uncategorized1 month agoOpinion: Are blue zones real? Answering that question is harder than ever
When French geneticist Jean-Francois Deleuze first launched the AGENOMICS study in 2022, he hoped to identify genetic patterns among 1,200 French citizens who’d lived more than...
-
Uncategorized1 month ago
FDA Action Alert: Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai and Cingulate
The FDA is looking at a slew of label expansions this month, including one that could open up home-based treatments for Alzheimer’s disease.
-
Uncategorized1 month ago
UCB bets $2 billion on Candid’s T cell engager ambitions
UCB bets $2 billion on Candid's T cell engager ambitions
-
Uncategorized1 month ago
Digital twins of ex vivo human lungs enable accurate and personalized evaluation of therapeutic efficacy
Nature Biotechnology, Published online: 04 May 2026; doi:10.1038/s41587-026-03121-4 A comprehensive ‘digital twin’ of a human organ has been built.
-
Uncategorized1 month agoStockWatch: Patient Death, Rival’s Patent Challenge Sink Erasca Shares
Sometimes a patient’s death is enough to send a stock tumbling. Other times, the fear of litigation that often arises whenever a new therapeutic approach emerges...
